We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently collaborated with the European Foundation for the Care of Newborn Infants (EFCNI) with a view to improve care for preterm born in Europe. This move is likely to boost Baxter’s Clinical Nutrition business.
Notably, Baxter will be raising awareness for the new standards released by EFCNI at the new European Standards of Care for Newborn Health lately.
Per management, preterm birth is one of the leading causes for neonatal mortality in Europe and accounts for more than half of all infant deaths. Globally, more than 15 million infants are born preterm annually. Moreover, European countries vary widely in providing care to newborns.
This is likely to increase the use of Baxter’s Numeta G13E triple-chamber PN product.
For investors’ notice, Numeta G13E was launched in Europe in 2016 to treat preterm infants who are at high risk for infection and malnutrition in the early days of their lives.
Clinical Nutrition in Focus
Baxter’s Clinical Nutrition solutions provide life-saving nutrition options. The company offers diverse and flexible nutrition solutions to meet different PN formulation needs.
In the last reported quarter, the unit contributed 7.8% to Baxter’s net sales. The unit saw strong growth internationally. In fact, management expects positive contribution from the Clinical Nutrition business in the next quarter.
It is also encouraging to note that EMEA sales grew 4% at constant currency in the last reported quarter.
Price Performance
Over the past year, shares of Baxter have rallied 1.3% against the industry’s 0.1% decline. The current level also compares favorably with the S&P 500 index’s decline of 1%.
The stock has a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , OPKO Health, Inc. (OPK - Free Report) and Surmodics (SRDX - Free Report) .
OPKO Health’s long-term earnings growth rate is projected at 12%. The stock carries a Zacks Rank of 2.
Surmodics’ long-term earnings growth rate is estimated at 10%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
Baxter International Inc. (BAX - Free Report) recently collaborated with the European Foundation for the Care of Newborn Infants (EFCNI) with a view to improve care for preterm born in Europe. This move is likely to boost Baxter’s Clinical Nutrition business.
Notably, Baxter will be raising awareness for the new standards released by EFCNI at the new European Standards of Care for Newborn Health lately.
Earlier this year, Baxter launched an educational video series on the appropriate use of PN (parenteral nutrition) to help reduce clinical malnutrition. (Read More: Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition)
Rationale
Per management, preterm birth is one of the leading causes for neonatal mortality in Europe and accounts for more than half of all infant deaths. Globally, more than 15 million infants are born preterm annually. Moreover, European countries vary widely in providing care to newborns.
This is likely to increase the use of Baxter’s Numeta G13E triple-chamber PN product.
For investors’ notice, Numeta G13E was launched in Europe in 2016 to treat preterm infants who are at high risk for infection and malnutrition in the early days of their lives.
Clinical Nutrition in Focus
Baxter’s Clinical Nutrition solutions provide life-saving nutrition options. The company offers diverse and flexible nutrition solutions to meet different PN formulation needs.
In the last reported quarter, the unit contributed 7.8% to Baxter’s net sales. The unit saw strong growth internationally. In fact, management expects positive contribution from the Clinical Nutrition business in the next quarter.
It is also encouraging to note that EMEA sales grew 4% at constant currency in the last reported quarter.
Price Performance
Over the past year, shares of Baxter have rallied 1.3% against the industry’s 0.1% decline. The current level also compares favorably with the S&P 500 index’s decline of 1%.
The stock has a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , OPKO Health, Inc. (OPK - Free Report) and Surmodics (SRDX - Free Report) .
Integer Holdings has an earnings growth rate of 31.2% for the next quarter and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
OPKO Health’s long-term earnings growth rate is projected at 12%. The stock carries a Zacks Rank of 2.
Surmodics’ long-term earnings growth rate is estimated at 10%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>